SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
ChemoCentryx, Inc. Reports Data for CCX872, the Company's Orally Bioavailable, Next-Generation CCR2 Inhibitor, in a Preclinical Model of Diabetic Nephropathy